Resources

Fill the information gaps by delivering more of the resources your patients need

Video Library

Get an in-depth look at several aspects of ZENPEP

Grace

PEP Talks with Mikhail Alper, PAC

Listen to Mikhail Alper discuss his approach to treating EPI and experience with ZENPEP

Watch the video

The science behind ZENPEP

Get an in-depth look at how EPI, pancreatic function, and ZENPEP are connected

Watch the video
Grace
Grace

Meet Dee

Hear Dee’s personal struggle with more than 30 years of undiagnosed EPI symptoms

Watch the video

ZENPEP Patient

Brochure

A brochure for patients and caregivers who want
to learn more about EPI symptoms, diagnosis,
and management goals

Download patient brochure

Z-Save® Mail-in

Rebate

A rebate form for ZENPEP patients who purchased
their medication at the pharmacy and were not
able to use their copay card

Download rebate form

Speaker Events

Reserve your place at the next event

Frequently Asked Questions

ZENPEP (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency.1

Yes. In the pivotal trial, patients with EPI due to CF achieved a mean coefficient of fat absorption (CFA) of 88.3% with ZENPEP vs 62.8% with placebo. The mean difference in CFA was 26 percentage points in favor of ZENPEP treatment (95% CI: 19%-32%); P≤0.001 (primary endpoint).1,2

EPI may cause the following symptoms: abdominal pain, bloating, excessive flatulence, frequent stools, nausea, malaise, diarrhea, and steatorrhea.3-5

In addition to the treatment of causative factors, there are 2 key goals for managing EPI: improving digestion and absorption of nutrients, and relieving GI symptoms of EPI. Management includes lifestyle and dietary modifications, vitamin and nutrient supplementation, and pancreatic enzyme replacement therapy.6-9

No. ZENPEP demonstrated results without the use of PPIs, H2-blockers, or motility agents in clinical studies.2

Dosage

  • ZENPEP is orally administered. Start ZENPEP at the lowest recommended dosage and individualize the dosage based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.1
    Infants (up to 12 months)
  • Infants may be given 3,000 lipase units (1 capsule) per 120 mL of formula or per breastfeeding1
  • Do not mix ZENPEP capsule contents directly into formula or breast milk prior to administration1
    Children Older Than 12 Months and Younger Than 4 Years
  • Enzyme dosing should begin with 1,000 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day1
    Children 4 Years and Older and Adults
  • Enzyme dosing should begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g of fat ingested per day1
  • Usually half of the prescribed ZENPEP dose for an individualized full meal should be given with each snack. The total daily dose should reflect approximately 3 meals plus 2 or 3 snacks per day1
    Limitations on Dosing
  • Do not exceed 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation.1
    For more information on dosing and administration, please see the full Prescribing Information for ZENPEP.

The most commonly reported AEs in Study 1 (≥6% of patients treated with ZENPEP) were headache, contusion, cough, and early satiety.1,2

No drug-related serious AEs were observed.2

Do not substitute other pancreatic enzyme products for ZENPEP. When switching from another pancreatic enzyme product to ZENPEP, monitor patients for clinical symptoms of exocrine pancreatic insufficiency and titrate the dosage as needed.1

CF=cystic fibrosis; CI=confidence interval; EPI=exocrine pancreatic insufficiency; GI=gastrointestinal; PPI=proton pump inhibitor.

Learn about dosing with ZENPEP
Discover how ZENPEP works

References: 1. ZENPEP. Package insert. Aimmune Therapeutics, Inc. Bridgewater, NJ; July 2025. 2. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8(6):405-417. doi:10.1016/j.jcf.2009.07.006 3. Ockenga J. Importance of nutritional management in diseases with exocrine pancreatic insufficiency. HPB (Oxford). 2009;11(suppl 3):11-15. doi:10.1111/j.1477-2574.2009.00134.x  4. Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72(2):e13066. doi:10.1111/ijcp.13066 5. Johnson CD, Arbuckle R, Bonner N, et al. Qualitative assessment of the symptoms and impact of pancreatic exocrine insufficiency (PEI) to inform the development of a patient-reported outcome (PRO) instrument. Patient. 2017;10(5):615-628. doi:10.1007/s40271-017-0233-0 6. Sikkens ECM, Cahen DL,van Eijck C, Kuipers EJ, Bruno MJ. Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a Dutch national survey. Pancreatology. 2012;12(1):71-73. doi:10.1016/j.pan.2011.12.010 7. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: chronic pancreatitis. Am J Gastroenterol. 2020;115(3):322-339. doi:10.14309/ajg.0000000000000535 8. Perbtani Y, Forsmark CE. Update on the diagnosis and management of exocrine pancreatic insufficiency. F1000Res. 2019;8:F1000 Faculty Rev-1991. doi:10.12688/f1000research.20779.1 9. Pancreatic Enzymes Clinical Care Guidelines. Cystic Fibrosis Foundation. Accessed October 20, 2025. https://www.cff.org/medical-professionals/pancreatic-enzymes-clinical-care-guidelines